<DOC>
	<DOCNO>NCT00868192</DOCNO>
	<brief_summary>The purpose study determine combination bevacizumab pemetrexed effect recurrent ovarian primary peritoneal carcinoma look progression survival 6 month .</brief_summary>
	<brief_title>Trial Pemetrexed Bevacizumab Recurrent Ovarian Primary Peritoneal Carcinoma</brief_title>
	<detailed_description>Patients treat pemetrexed 500 mg/m2 IV Bevacizumab 15 mg/kg IV every 3 weeks.The patient treat indefinitely side effect deem severe investigator progression . Disease progression measure every 6 week use RECIST criterion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Recurrent epithelial ovarian primary peritoneal carcinoma . Histologic confirmation primary tumor require . Patients borderline tumor eligible . Patients must measurable disease . Measurable disease define least one lesion accurately measure one dimension ( long dimension record ) . Each lesion must &gt; 20 mm measure conventional imaging technique , include plain radiography , compute tomography MRI &gt; 10 mm measure spiral CT . Patients must least one `` target lesion '' ass response RECIST criterion . Lesions within previously irradiate field consider `` nontarget '' lesion . Patients must GOG performance status 0 1 . Patients must ability interrupt nonsteroidal antiinflammatory ( NSAID ) treatment 2 day ( 5 day longacting NSAIDs ) , day , 2 day follow administration pemetrexed . Patients must ability take folic acid , vitamin B12 dexamethasone describe per protocol . Recovery effect recent surgery , radiotherapy chemotherapy . Patients free active infection require antibiotic . Any hormonal therapy direct tumor must discontinue least one week prior registration . Continuation hormone replacement therapy ( HRT ) permit . Any prior therapy direct malignant tumor , include immunologic agent cytotoxic agent , must discontinue least three week prior registration . Patients must one prior platinumbased chemotherapeutic regimen management primary disease contain carboplatin , cisplatin , another organoplatinum compound . This initial treatment may include highdose therapy , consolidation , extend therapy administer surgical nonsurgical assessment . Patients must one prior regimen contain taxane compound . Patient may receive firstline treatment either intravenously intraperitoneally . Patients must NOT receive prior therapy pemetrexed bevacizumab . Patients may receive total &lt; 2 prior cytotoxic chemotherapy regimen ( adjuvant therapy plus one additional regimen ) . Consolidation extend therapy part first line treatment consider single regimen . Bone marrow function : absolute neutrophil count ( ANC ) great equal 1,500/ul , equivalent Common Toxicity Criteria ( CTC ) grade 1 ; Platelets great equal 100,000/ul . Creatinine clearance must great 45 ml/min . Hepatic function : bilirubin le equal 1.5 x ULN . AST alkaline phosphatase less equal 2.5 x ULN . Neurologic function : neuropathy ( sensory motor ) less equal CTC grade 1 . Coagulation : prothrombin time ( PT ) international normalize ratio ( INR ) &lt; 1.5 ( INR may 2 3 patient stable dose therapeutic warfarin ) PTT &lt; 1.2 time control . Patients must sign informed consent . Patients must meet preentry requirement . Patients childbearing potential must negative serum pregnancy test prior study entry , practice effective form contraception , lactate . Patients may receive prior radiotherapy ( le 25 % bone marrow ) , must start Level 1 dose reduction . Patients serious , nonhealing wound , ulcer bone fracture . Patients clinically significant cardiovascular disease : Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) Any prior history hypertensive crisis hypertensive encephalopathy . Unstable angina within 6 month prior study enrollment . New York Heart Association ( NYHA ) grade II great congestive heart failure . Serious cardiac arrhythmia require medication . Grade II great peripheral vascular disease . Patients claudication within 6 month . History myocardial infarction within 6 month . Patients active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel . Patients presence ascites third space fluid control drainage . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day 1 study anticipation need major surgical procedure course study . Patients history evidence upon physical examination central nervous system disease , include primary brain tumor , brain metastasis , seizure control standard medical therapy , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage within 6 month first date treatment study . Minor surgical procedure , central venous access placement , fine needle aspiration core biopsy within 7 day prior day 1 study . Patients proteinuria . At baseline patient undergo urine proteincreatinine ratio ( UPCR ) ( Appendix IV ) . Patients UPCR &gt; 1.0 screening exclude . Urine dipstick proteinuria may also use . Urine dipstick proteinuria ≥ 2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Patients whose circumstance permit completion study require followup . Patients pregnant nursing . Patients age 18 . Patients invasive malignancy , exception nonmelanoma skin cancer , ( ) evidence cancer within last 5 year whose previous cancer treatment contraindicate protocol . Prior therapy antiangiogenic agent pemetrexed . Patients active infection require parenteral antibiotic . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month . Partial complete small large bowel obstruction demonstrate radiographically within 3 month prior study . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study . Known hypersensitivity component bevacizumab . Inability comply study and/or followup procedure . Life expectancy le 12 week .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>